249 related articles for article (PubMed ID: 16545478)
1. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene.
Zhang C; Tang N; Liu X; Liang W; Xu W; Torchilin VP
J Control Release; 2006 May; 112(2):229-39. PubMed ID: 16545478
[TBL] [Abstract][Full Text] [Related]
2. [Cell penetrating peptides enhance intracellular translocation and function of siRNA encapsulated in Pegylated liposomes].
Wang W; Tang N; Zhang CL; Liu XJ; Hu H; Zhang ZX; Liang W
Yao Xue Xue Bao; 2006 Feb; 41(2):142-8. PubMed ID: 16671545
[TBL] [Abstract][Full Text] [Related]
3. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
Şalva E; Turan SÖ; Eren F; Akbuğa J
Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
[TBL] [Abstract][Full Text] [Related]
4. Delivery of siRNA Using Cationic Liposomes Incorporating Stearic Acid-modified Octa-Arginine.
Yang D; Li Y; Qi Y; Chen Y; Yang X; Li Y; Liu S; Lee RJ
Anticancer Res; 2016 Jul; 36(7):3271-6. PubMed ID: 27354583
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy of liposome-mediated vascular gene therapy via lipid surface modifications.
Fisher RK; Mattern-Schain SI; Best MD; Kirkpatrick SS; Freeman MB; Grandas OH; Mountain DJH
J Surg Res; 2017 Nov; 219():136-144. PubMed ID: 29078873
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
7. Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells.
Golan M; Feinshtein V; David A
Eur J Pharm Biopharm; 2016 Dec; 109():103-112. PubMed ID: 27702685
[TBL] [Abstract][Full Text] [Related]
8. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
[TBL] [Abstract][Full Text] [Related]
9. CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array.
Haigh O; Depelsenaire AC; Meliga SC; Yukiko SR; McMillan NA; Frazer IH; Kendall MA
J Control Release; 2014 Nov; 194():148-56. PubMed ID: 25192942
[TBL] [Abstract][Full Text] [Related]
10. Coated microneedles mediated intradermal delivery of octaarginine/BRAF siRNA nanocomplexes for anti-melanoma treatment.
Ruan W; Zhai Y; Yu K; Wu C; Xu Y
Int J Pharm; 2018 Dec; 553(1-2):298-309. PubMed ID: 30347273
[TBL] [Abstract][Full Text] [Related]
11. cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells.
Khatri N; Baradia D; Vhora I; Rathi M; Misra A
J Control Release; 2014 May; 182():45-57. PubMed ID: 24631861
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of optimized liposomes for delivery of small interfering RNA.
Yang T; Bantegui T; Pike K; Bloom R; Phipps R; Bai S
J Liposome Res; 2014 Dec; 24(4):270-9. PubMed ID: 24708056
[TBL] [Abstract][Full Text] [Related]
13. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
[TBL] [Abstract][Full Text] [Related]
15. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
[TBL] [Abstract][Full Text] [Related]
16. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery.
Tang J; Fu H; Kuang Q; Zhang L; Zhang Q; Liu Y; Ran R; Gao H; Zhang Z; He Q
J Drug Target; 2014 May; 22(4):313-26. PubMed ID: 24404866
[TBL] [Abstract][Full Text] [Related]
17. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
Sonoke S; Ueda T; Fujiwara K; Kuwabara K; Yano J
Biol Pharm Bull; 2011; 34(8):1338-42. PubMed ID: 21804229
[TBL] [Abstract][Full Text] [Related]
18. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
19. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics.
Mattern-Schain SI; Fisher RK; West PC; Grimsley LB; Harris TM; Grandas OH; Best MD; Mountain DJH
Chem Phys Lipids; 2019 Jan; 218():149-157. PubMed ID: 30582896
[TBL] [Abstract][Full Text] [Related]
20. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
